Physician profile
Perry Fuchs
NPI 1497287122
$2,463.68
in general payments reported to CMS, 2019-2025
25 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $453 · 2024: $774 · 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,401 · Education: $62.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,400.93 |
| Education | $62.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $597.79 | 2023-2025 | Tavneos, Evenity, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $350.26 | 2023-2025 | Saphnelo |
| Ucb, INC. | $222.79 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $222.02 | 2024-2025 | |
| Glaxosmithkline, LLC. | $163.90 | 2023-2025 | Benlysta, Shingrix, Arexvy |
| Radius Health, INC. | $138.77 | 2024-2025 | Tymlos |
| Celltrion USA INC. | $105.11 | 2023-2025 | Yuflyma, Vegzelma |
| Abbvie INC. | $86.89 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $69.70 | 2023 | Acthar |
| Ani Pharmaceuticals, INC. | $53.32 | 2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $47.97 | 2024-2025 | Strensiq |
| Alvogen INC | $45.21 | 2023 | Teriparatide |
| Kiniksa Pharmaceuticals International, Plc | $44.85 | 2024 | Arcalyst |
| Fresenius Kabi USA, LLC | $41.32 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $34.49 | 2023 | Arcalyst |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $34.40 | 2025 | |
| Genzyme Corporation | $31.94 | 2024-2025 | |
| Organon LLC | $30.89 | 2025 | Hadlima, Renflexis |
| Kyowa Kirin, INC. | $25.34 | 2025 | |
| Janssen Biotech, INC. | $23.92 | 2023 | Simponi Aria |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.36 | 2024 | |
| Lilly USA, LLC | $21.67 | 2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $17.79 | 2024 | Orencia |
| Sandoz INC. | $15.11 | 2023 | Hyrimoz |
| Pfizer INC. | $14.87 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perry Fuchs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.